Edition:
United States

Enanta Pharmaceuticals Inc (ENTA.OQ)

ENTA.OQ on NASDAQ Stock Exchange Global Select Market

72.77USD
3:59pm EST
Change (% chg)

$-2.00 (-2.67%)
Prev Close
$74.77
Open
$74.73
Day's High
$75.38
Day's Low
$72.29
Volume
131,762
Avg. Vol
101,344
52-wk High
$127.74
52-wk Low
$48.57

Latest Key Developments (Source: Significant Developments)

Enanta Pharmaceuticals Reports Q2 Earnings Per Share $0.61
Tuesday, 8 May 2018 04:00pm EDT 

May 8 (Reuters) - Enanta Pharmaceuticals Inc ::ENANTA PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR ITS FISCAL SECOND QUARTER ENDED MARCH 31, 2018.Q2 EARNINGS PER SHARE $0.61.Q2 EARNINGS PER SHARE VIEW $0.53 -- THOMSON REUTERS I/B/E/S.ROYALTY REVENUE FOR QUARTER INCREASED TO $44.0 MILLION DUE TO INCREASE IN ABBVIE'S MAVYRET SALES.QTRLY TOTAL REVENUE WAS $44.0 MILLION, COMPARED TO $9.0 MILLION.  Full Article

Enanta Pharmaceuticals Says Phase 1 Clinical Study Of Edp-938 For Respiratory Syncytial Virus Initiated
Friday, 5 Jan 2018 07:30am EST 

Jan 5 (Reuters) - Enanta Pharmaceuticals Inc ::ENANTA PHARMACEUTICALS TO PROVIDE UPDATES ON ITS RESEARCH AND DEVELOPMENT PROGRAMS AND BUSINESS OUTLOOK FOR 2018 DURING THE 36TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE.ENANTA PHARMACEUTICALS INC - PHASE 1 CLINICAL STUDY OF EDP-938 FOR RESPIRATORY SYNCYTIAL VIRUS INITIATED.ENANTA PHARMACEUTICALS INC - PHASE 2 CLINICAL STUDY "INTREPID" OF EDP-305 IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS INITIATED.ENANTA PHARMACEUTICALS INC - STRONG CASH BALANCE OF $294M AS OF SEPTEMBER 30, 2017 TO SUPPORT ADVANCING RESEARCH AND DEVELOPMENT PROGRAMS.  Full Article

Enanta Pharma Q4 earnings per share $1.86
Monday, 20 Nov 2017 04:01pm EST 

Nov 20 (Reuters) - Enanta Pharmaceuticals Inc ::Enanta Pharmaceuticals reports financial results for its fourth quarter and year ended september 30, 2017.Q4 earnings per share $1.86.Q4 revenue $75.9 million versus I/B/E/S view $73.1 million.Q4 earnings per share view $2.13 -- Thomson Reuters I/B/E/S.  Full Article